- Home
- KXIN vs VBIO Comparison
KXIN vs VBIO Comparison
Compare KXIN & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | VBIO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.6M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KXIN | VBIO |
|---|---|---|
| Price | $1.29 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 507.0K |
| Earning Date | 11-26-2019 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.11 | $0.11 |
| 52 Week High | $22.00 | $4.14 |
Technical Indicators
Market Signals| Indicator | KXIN | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 30.56 | 56.78 |
| Support Level | $0.42 | $2.05 |
| Resistance Level | $1.28 | $4.14 |
| Average True Range (ATR) | 0.25 | 0.46 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 15.10 | 39.37 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.